Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

1
SUN Mobility plans up to 100 battery swapping stations by FY19 end

1h livemint
Mumbai: In a boost to India’s electric vehicle (EV) infrastructure network, Chetan Maini-led start-up SUN Mobility plans to set up the first batch of its battery-swapping stations for electric two and three-wheelers across the country in the last quarter of this fiscal, a senior executive said on Thursday. The Bengaluru-based start-up is yet to set up any pilot stations, since it had been focusing on developing the core technology so far.
MSFT 500477 AKLS AKLD ASHOKLEY

4
Tata Motors, Mahindra top RD spenders in auto industry

4h moneycontrol
Homegrown companies Tata Motors and Mahindra & Mahindra were the biggest spenders on research and development in 2016-17 among 25 automakers in India which together invested Rs 6,344 crore, latest industry data showed.
BAJAJ-AUTO 532977 505200 CMQMY CUMMINSIND HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500033 ASHOKLEY ECQRY FORCEMOT MRZUY AKLD 532500 500182 500480 MARUTI 7269 501455 HRTQY GREAVESCOT AKLS TTM

4
Auto stocks skid on proposed tax on petrol, diesel cars

2018-07-11 livemint
New Delhi: Investors on Wednesday dumped auto stocks following reports that the finance ministry is considering a proposal for higher taxes on petrol and diesel cars to push adoption of electric vehicles in India. The Auto Index of the BSE fell to a six-month low to 24,838.52 even as the benchmark Sensex rose 0.07%, or 26.31 points, to 36,265.93.
ECQRY AKLD 500182 505200 HEROMOTOCO 500477 HRTQY 500570 TATAMOTORS EICHERMOT AKLS ASHOKLEY TTM

0
Ashok Leyland Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500477 AKLS AKLD ASHOKLEY

4
Tata Motors’ healthy sales growth comes at a price

2018-07-11 livemint
Tata Motors Ltd’s standalone business has been forging ahead with strong double-digit sales growth in commercial vehicles (CVs) and passenger vehicles (PVs). However, it looks like the automobile juggernaut is beginning to pay a price for sustaining this growth.
500477 500570 AKLS TATAMOTORS AKLD TTM ASHOKLEY

4
Liberty House to complete Adhunik Metaliks acquisition in 2 months

2018-07-09 moneycontrol
Liberty House, part of the UK-based GFG Alliance, will look to complete the acquisition of Adhunik Metaliks within two months after securing a green signal from the latter’s creditors.
AMKD 517146 513691 UHBTY 532727 AMTEKAUTO AKLD USHAMART ABGSHIP 532682 JMTAUTOLTD ADHUNIK 500477 500570 MAHSEAMLES 520077 TATAMOTORS AKLS 500265 ASHOKLEY TTM

0
Ashok Leyland plans to take its Optare electric bus to new markets

2018-07-08 livemint
New Delhi: Hinduja Group flagship company Ashok Leyland Ltd is gearing up to expand its light commercial vehicle business, international operations and defence mobility segment, even as it looks to take the proven success of its Optare electric bus in the UK to other countries.
500477 AKLS AKLD ASHOKLEY

0
Kotak Securities upgrades Ashok Leyland to buy; slowdown concerns is overdone

2018-07-06 moneycontrol
Shares of Ashok Leyland surged 6 percent intraday Friday as broking house Kotak Securities has upgraded the stock to buy from add rating with a target of Rs 160 share.
500477 AKLS AKLD ASHOKLEY

4
Over 160 stocks hit fresh 52-week low on BSE; DEN Networks, Hathway, BHEL, Andhra Bank top losers

2018-07-06 moneycontrol
The Indian benchmark indices are trading on a positive note this Friday afternoon with the Nifty adding 47 points and is trading at 10,796 mark. The Sensex is trading higher by 147 points at 35,722.
BAJAJ-AUTO 532938 CAPF 532418 532977 514034 532953 533137 VISASTEEL DEN 533644 532121 INOXWIND JBFIND VGUARD 500477 500570 BEL 500493 TATAMOTORS BHARATFORG ASHOKLEY BHQRY CONART 532721 AKLD FINOLEXIND UJAAS 501455 500940 522231 500049 GREAVESCOT 539083 DENABANK AKLS ANDHRABANK TTM

4
CV, tractor sales continue to zoom in June

2018-07-03 moneycontrol
Automobile players continue to clock strong volume growth in June. Performance continues to be robust for all segments because of the base effect. The transition towards Goods & Services Tax (GST) led to de-stocking last year and consequently very little offtake in June 2017.
BAJAJ-AUTO ECQRY TVSMOTOR 532977 AKLD 500182 505200 532343 HEROMOTOCO 500477 HRTQY 500570 TATAMOTORS EICHERMOT AKLS ASHOKLEY TTM

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...